ZNTL (Zentalis Pharma) צמיחת רווח נקי למניה השנה

Zentalis Pharmaceuticals (ZNTL) is developing targeted oncology therapies while remaining in a stage of costly research and regular secondary offerings. The company is expanding partnerships with medical centers to combat cancer cell survival. The proportional growth of EPS compared to last year on the GURU.Markets daily chart shows a value of 5.40, reflecting the current metric amid a stable scientific team and the strategic hiring of compliance experts.
פילוחי מדדים פיננסיים ומדדי שוק עבור Zentalis Pharma (ZNTL)

Zentalis Pharmaceuticals (ZNTL) specializes in developing high-precision small molecules for cancer therapy. The growth rate of net income per share compared to last year reflects the commercialization efficiency of these developments. This metric calculates the percentage deviation of the current EPS from the same period last year, capturing the real acceleration of the business. The positive trend confirms the monetization of the company's scientific achievements. It is critical for investors to correlate this growth with the debt load to avoid overpaying.